Last Updated: November 8, 2026

RESERPINE AND HYDROCHLOROTHIAZIDE Drug Patent Profile

Name: RESERPINE AND HYDROCHLOROTHIAZIDE Drug Patent, Exclusivity, and Generic Launch Dataset
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

« Back to Dashboard

Which patents cover Reserpine And Hydrochlorothiazide, and what generic alternatives are available?

Reserpine And Hydrochlorothiazide is a drug marketed by Barr, Sandoz, and West Ward. and is included in four NDAs.

The generic ingredient in RESERPINE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; reserpine. There is one drug master file entry for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for RESERPINE AND HYDROCHLOROTHIAZIDE?
What are the global sales for RESERPINE AND HYDROCHLOROTHIAZIDE?
What is Average Wholesale Price for RESERPINE AND HYDROCHLOROTHIAZIDE?

Summary for RESERPINE AND HYDROCHLOROTHIAZIDE

US Patents:	0
Applicants:	3
NDAs:	4
Raw Ingredient (Bulk) Api Vendors:	101
Clinical Trials:	2
DailyMed Link:	RESERPINE AND HYDROCHLOROTHIAZIDE at DailyMed

Drug patent expirations by year for RESERPINE AND HYDROCHLOROTHIAZIDE

Recent Clinical Trials for RESERPINE AND HYDROCHLOROTHIAZIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
West China Hospital	Phase 4
VA Office of Research and Development
US Department of Veterans Affairs

See all RESERPINE AND HYDROCHLOROTHIAZIDE clinical trials

US Patents and Regulatory Information for RESERPINE AND HYDROCHLOROTHIAZIDE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Barr	RESERPINE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; reserpine	TABLET;ORAL	084580-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
West Ward	RESERPINE AND HYDROCHLOROTHIAZIDE-50	hydrochlorothiazide; reserpine	TABLET;ORAL	088189-001	May 10, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Barr	RESERPINE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; reserpine	TABLET;ORAL	084579-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Sandoz	RESERPINE AND HYDROCHLOROTHIAZIDE	hydrochlorothiazide; reserpine	TABLET;ORAL	088200-001	Jan 31, 1984		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.